drugset / Trial / NCT04359537

Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19

NCT04359537

Phase 2 Unknown 200 enrolled Shaheed Zulfiqar Ali Bhutto Medical University
RandomizedParallel-groupSingle-blindPrevention

Summary

Hydroxychloroquine has been approved by FDA as one of the treatment options for COVID 19.Healthcare personnel are amongst those at highest risk to contract the disease. Several health authorities are now recommending the use of hydroxychloroquine as pre-exposure prophylaxis is in health care personnel. Several studies are on going in this context. However there is a controversy regarding the dosage regimen. This drug has a half life of 22.4 days. In this study we will be comparing three different doses of Hydroxychloroquine and additionally have a control group in order to determine the efficacy of hydroxychloroquine as pre- exposure prophylaxis in healthcare personnel in various doses.

Timeline

Start
2020-05-01
Primary completion
2020-08-25
Completion
2020-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 200 mg Oral
Subject Hydroxychloroquine Small molecule 400 mg Oral

Indications